MARCY GABAY: Open Payments
NPI 1760791578 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$841 in 44 payments from 10 companies in 2025. Trend: 2023 $238 · 2024 $459 · 2025 $841
Food & beverage: $841
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $254 |
| Janssen Biotech, Inc. | 9 | $170 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $100 |
| Celltrion USA Inc. | 2 | $45 |
| Ardelyx, Inc. | 2 | $41 |
| GENZYME CORPORATION | 1 | $30 |
| VIVUS LLC | 1 | $21 |
| Intercept Pharmaceuticals, Inc. | 1 | $18 |
| IRONWOOD PHARMACEUTICALS, INC | 1 | $17 |
Products named: TREMFYA, RINVOQ, XIFAXAN, ENTYVIO, CREON, RELISTOR, VEGZELMA, IBSRELA.
Industry payments across FL — which companies pay providers there.
